Table 4.
Disclosure of PrEP use by month three and housing with parents at month three on PrEP adherence at months three and six
| Increase in DBS TFV-DP concentration | ||||||||
|---|---|---|---|---|---|---|---|---|
| Month three adherencea | Month six adherencea | |||||||
| Average (95% CI) |
fmol/punch (95% CI) | T test | P value | Average (95% CI) |
fmol/punch (95% CI) | T test | P value | |
| Disclosed to parents and live with parents (n = 84) | 431 (372, 490) | 90 (− 20, 199) | 1.60 | 0.11 | 308 (238, 379) | 50 (− 92, 193) | 0.69 | 0.49 |
| Disclosed to parents but does not live with parents (n = 143) | 472 (392, 554) | 74 (− 42, 191) | 1.26 | 0.21 | 461 (344, 578) | 159 (6, 312) | 2.04 | 0.04 |
| Did not disclose to parents (n = 108) | 397 (308, 485) | Ref | 333 (223, 442) | Ref | ||||
DBS TFV-DP tenofovir-diphosphate concentrations in dried blood spots, CI confidence interval
aAdjusted for site and age